Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Assess the Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Setrusumab (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 16 Sep 2025 Rote assumed from the RDI
- 09 Sep 2022 This study was conducted and previously posted by Novartis. The record was transferred toUltragenyx in February 2021.
- 25 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.